Baseline characteristics and consolidation/salvage treatment after first-line intra-arterial or intravenous chemotherapy
| IAC | IVC | p Value | |
|---|---|---|---|
| Number of eyes | 25 | 23 | |
| Number of cycles/injections | 2.7±0.5 | 3.0±0.8 | |
| Age (months) at first cycle/injection | 33.3±25.9 | 19.2±15.2 | 0.01* |
| Baseline characteristics | |||
| Retinal detachment (n) | 9 | 11 | 0.56† |
| Total retinal detachment | 5 | 8 | |
| Partial retinal detachment | 3 | 2 | |
| Peritumoral retinal detachment | 1 | 1 | |
| None/reapplied | 12/4 | 7/5 | |
| Macula | |||
| Intact | 7 | 7 | |
| Damaged/absent | 18 | 16 | 0.89 |
| Subretinal seeding | 9 | 10 | 0.77† |
| Vitreous seeding (No. of eyes) | 20 | 14 | 0.21† |
| Localised | 2 | 7 | |
| Diffuse | 18 | 7 | |
| Consolidation treatment (No. of eyes) | |||
| CTT±focal CTP | 0 | 9 | |
| CTT+IViC±focal CTP | 0 | 1 | |
| CTT+PBT±focal CTP | 0 | 1 | |
| PBT±focal CTP | 0 | 2 | |
| Focal CTP only | 5 | 5 | |
| IViC±focal CTP | 9 | 0 | |
| IViC+POC±focal CTP | 3 | 0 | |
| POC±focal CTP | 3 | 0 | |
| None | 5 | 1 | |
| Relapse (No. of eyes) | 6 (24%) | 12 (52%) | 0.07† |
| Mean number of relapses | 1.3 ±0.8 | 3.3±1.6 | 0.01* |
| Months to first relapse | 6.3±2.5 | 8.5±3.8 | 0.61* |
| At primary tumour site (n) | 0 | 8 | |
| Subretinal seeding (n) | 2 | 7 | |
| Vitreous seeding (n) | 4 | 4 | |
| None | 19 | 7 | |
| Salvage treatment (No. of eyes) | 6 | 12 | 0.07† |
| CTT+PBT±focal CTP | 0 | 1 | |
| PBT±focal CTP | 0 | 3 | |
| POC±focal CTP | 0 | 1 | |
| IViC+POC±focal CTP | 0 | 1 | |
| IViC+POC+PBT±focal CTP | 0 | 1 | |
| IViC±focal CTP | 3 | 0 | |
| IViC+PBT±focal CTP | 1 | 0 | |
| Focal CTP only | 1 | 5 | |
| IAC (repeat)+IViC+focal CTP | 1 | 0 | |
| Outcome | |||
| Enucleated eyes (n) | 0 | 10 (43%) | <0.001† |
| Progressive disease | – | 9 | |
| Phthisis bulbi | – | 1 | |
| Time to complete response | |||
| Retained eyes | 6.7±3.0 | 14.2±6.5 | <0.001* |
| Globe survival from first cycle/injection (months) | 33.0± 17.7 | 62.7± 55.7 | |
| Enucleated eyes | – | 16.5 (0.8–48.4) | |
| Retained eyes | 33.0± 17.7 | 91.4±54.3 | |
| Event-free interval for retained eyes (months) | 28.2 (3.5–67.9) | 78.5 (4.7–203.4) | |
| Patient survival | 33.3 (9.1–75.1) | 100.5 (19.3–218.6) | |
| Final visual acuity logMAR (median and IQR) | 0.7 [0.2–1.0] | 1.4 [1.2–2.0] | 0.01 |
*Mann-Whitney U test.
†Fisher's exact test.
CTT, chemothermotherapy; focal CTP, cryocoagulation±thermotherapy±photocoagulation; IAC, intra-arterial chemotherapy; IVC, intravenous chemotherapy; IViC, intravitreal chemotherapy; logMAR, logarithm of the minimum angle of resolution; PBT, plaque brachytherapy; POC, periocular chemotherapy.